Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
16
ABVC Quote, Financials, Valuation and Earnings
Last price:
$2.20
Seasonality move
:
-8.29%
Day range:
$2.03 - $2.09
52-week range:
$0.40 - $5.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
44.40x
P/B ratio:
4.11x
Volume:
52.1K
Avg. volume:
65.6K
1-year change:
320.62%
Market cap:
$49.6M
Revenue:
$509.6K
EPS (TTM):
-$0.22
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ABVC
ABVC BioPharma, Inc.
|
-- | -- | -- | -- | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.20 | -- | -26.67% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ABVC
ABVC BioPharma, Inc.
|
$2.04 | -- | $49.6M | -- | $0.00 | 0% | 44.40x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$2.95 | $0.85 | $371.7M | 4.96x | $0.80 | 0% | 5.73x |
|
NNVC
NanoViricides, Inc.
|
$1.21 | $6.50 | $21.8M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.82 | $2.00 | $678.8K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.18 | $7.00 | $5.9M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ABVC
ABVC BioPharma, Inc.
|
17.7% | -0.717 | 3.52% | 0.24x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ABVC
ABVC BioPharma, Inc.
|
$699.9K | -$1.2M | -40.7% | -54.57% | -146.78% | -$138.7K |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
ABVC BioPharma, Inc. vs. Competitors
-
Which has Higher Returns ABVC or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -161.75% compared to ABVC BioPharma, Inc.'s net margin of -255.85%. ABVC BioPharma, Inc.'s return on equity of -54.57% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital ABVCABVC BioPharma, Inc.87.93% -$0.05 $17.1M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About ABVC or NBY?
ABVC BioPharma, Inc. has a consensus price target of --, signalling upside risk potential of 890.2%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -71.19%. Given that ABVC BioPharma, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe ABVC BioPharma, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ABVCABVC BioPharma, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is ABVC or NBY More Risky?
ABVC BioPharma, Inc. has a beta of 0.243, which suggesting that the stock is 75.704% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock ABVC or NBY?
ABVC BioPharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. ABVC BioPharma, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ABVC or NBY?
ABVC BioPharma, Inc. quarterly revenues are $796K, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. ABVC BioPharma, Inc.'s net income of -$1.3M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, ABVC BioPharma, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 4.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ABVC BioPharma, Inc. is 44.40x versus 5.73x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ABVCABVC BioPharma, Inc.44.40x -- $796K -$1.3M NBYNovaBay Pharmaceuticals, Inc.5.73x 4.96x $521K -$1.3M
-
Which has Higher Returns ABVC or NNVC?
NanoViricides, Inc. has a net margin of -161.75% compared to ABVC BioPharma, Inc.'s net margin of --. ABVC BioPharma, Inc.'s return on equity of -54.57% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital ABVCABVC BioPharma, Inc.87.93% -$0.05 $17.1M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About ABVC or NNVC?
ABVC BioPharma, Inc. has a consensus price target of --, signalling upside risk potential of 890.2%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 437.19%. Given that ABVC BioPharma, Inc. has higher upside potential than NanoViricides, Inc., analysts believe ABVC BioPharma, Inc. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ABVCABVC BioPharma, Inc.0 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is ABVC or NNVC More Risky?
ABVC BioPharma, Inc. has a beta of 0.243, which suggesting that the stock is 75.704% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock ABVC or NNVC?
ABVC BioPharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ABVC BioPharma, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ABVC or NNVC?
ABVC BioPharma, Inc. quarterly revenues are $796K, which are larger than NanoViricides, Inc. quarterly revenues of --. ABVC BioPharma, Inc.'s net income of -$1.3M is higher than NanoViricides, Inc.'s net income of -$1.8M. Notably, ABVC BioPharma, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ABVC BioPharma, Inc. is 44.40x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ABVCABVC BioPharma, Inc.44.40x -- $796K -$1.3M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns ABVC or OGEN?
Oragenics, Inc. has a net margin of -161.75% compared to ABVC BioPharma, Inc.'s net margin of --. ABVC BioPharma, Inc.'s return on equity of -54.57% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital ABVCABVC BioPharma, Inc.87.93% -$0.05 $17.1M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About ABVC or OGEN?
ABVC BioPharma, Inc. has a consensus price target of --, signalling upside risk potential of 890.2%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 142.45%. Given that ABVC BioPharma, Inc. has higher upside potential than Oragenics, Inc., analysts believe ABVC BioPharma, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ABVCABVC BioPharma, Inc.0 0 0 OGENOragenics, Inc.1 0 0 -
Is ABVC or OGEN More Risky?
ABVC BioPharma, Inc. has a beta of 0.243, which suggesting that the stock is 75.704% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock ABVC or OGEN?
ABVC BioPharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ABVC BioPharma, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ABVC or OGEN?
ABVC BioPharma, Inc. quarterly revenues are $796K, which are larger than Oragenics, Inc. quarterly revenues of --. ABVC BioPharma, Inc.'s net income of -$1.3M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, ABVC BioPharma, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ABVC BioPharma, Inc. is 44.40x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ABVCABVC BioPharma, Inc.44.40x -- $796K -$1.3M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns ABVC or PTN?
Palatin Technologies has a net margin of -161.75% compared to ABVC BioPharma, Inc.'s net margin of --. ABVC BioPharma, Inc.'s return on equity of -54.57% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ABVCABVC BioPharma, Inc.87.93% -$0.05 $17.1M PTNPalatin Technologies-- -- -- -
What do Analysts Say About ABVC or PTN?
ABVC BioPharma, Inc. has a consensus price target of --, signalling upside risk potential of 890.2%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than ABVC BioPharma, Inc., analysts believe Palatin Technologies is more attractive than ABVC BioPharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ABVCABVC BioPharma, Inc.0 0 0 PTNPalatin Technologies0 0 0 -
Is ABVC or PTN More Risky?
ABVC BioPharma, Inc. has a beta of 0.243, which suggesting that the stock is 75.704% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock ABVC or PTN?
ABVC BioPharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ABVC BioPharma, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ABVC or PTN?
ABVC BioPharma, Inc. quarterly revenues are $796K, which are larger than Palatin Technologies quarterly revenues of --. ABVC BioPharma, Inc.'s net income of -$1.3M is higher than Palatin Technologies's net income of --. Notably, ABVC BioPharma, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ABVC BioPharma, Inc. is 44.40x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ABVCABVC BioPharma, Inc.44.40x -- $796K -$1.3M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns ABVC or TOVX?
Theriva Biologics, Inc. has a net margin of -161.75% compared to ABVC BioPharma, Inc.'s net margin of --. ABVC BioPharma, Inc.'s return on equity of -54.57% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital ABVCABVC BioPharma, Inc.87.93% -$0.05 $17.1M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About ABVC or TOVX?
ABVC BioPharma, Inc. has a consensus price target of --, signalling upside risk potential of 890.2%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3897.72%. Given that Theriva Biologics, Inc. has higher upside potential than ABVC BioPharma, Inc., analysts believe Theriva Biologics, Inc. is more attractive than ABVC BioPharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ABVCABVC BioPharma, Inc.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is ABVC or TOVX More Risky?
ABVC BioPharma, Inc. has a beta of 0.243, which suggesting that the stock is 75.704% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock ABVC or TOVX?
ABVC BioPharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ABVC BioPharma, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ABVC or TOVX?
ABVC BioPharma, Inc. quarterly revenues are $796K, which are larger than Theriva Biologics, Inc. quarterly revenues of --. ABVC BioPharma, Inc.'s net income of -$1.3M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, ABVC BioPharma, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ABVC BioPharma, Inc. is 44.40x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ABVCABVC BioPharma, Inc.44.40x -- $796K -$1.3M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
55
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
35
SMX alert for Dec 19
SMX (Security Matters) Plc [SMX] is up 11.91% over the past day.
Sell
36
INSP alert for Dec 19
Inspire Medical Systems, Inc. [INSP] is up 1.39% over the past day.
Sell
40
INSM alert for Dec 19
Insmed, Inc. [INSM] is up 4.79% over the past day.
